Used in cancer immunotherapy research, particularly in targeting tumors expressing CEACAM1 (CD66a), such as melanoma, prostate, and colorectal cancers. This reference antibody serves as a tool for blocking immune checkpoint pathways, potentially enhancing T-cell activation and anti-tumor immune responses. It is also employed in diagnostic assays to detect CEACAM1 expression in tissue samples, aiding in disease characterization and patient stratification. Due to its origin from a medical center patent, it supports the development of therapeutic antibodies and biosimilars in clinical and preclinical studies.